HC Wainwright Has Strong Outlook for Invivyd FY2026 Earnings

Invivyd, Inc. (NASDAQ:IVVD) – Research analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Invivyd in a note issued to investors on Tuesday, August 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.46) for the year, up from their prior forecast of ($0.48). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for Invivyd’s Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.12 EPS, FY2029 earnings at $0.52 EPS and FY2030 earnings at $1.10 EPS.

Other research analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Finally, Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Invivyd has a consensus rating of “Hold” and a consensus price target of $8.00.

Invivyd Trading Up 10.3%

Shares of NASDAQ:IVVD opened at $0.96 on Thursday. The firm has a market cap of $282.82 million, a price-to-earnings ratio of -2.91 and a beta of 0.71. Invivyd has a 1 year low of $0.48 and a 1 year high of $3.07. The business has a fifty day simple moving average of $0.77 and a 200 day simple moving average of $1.23.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The company had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Chicago Partners Investment Group LLC bought a new position in shares of Invivyd in the 1st quarter valued at approximately $25,000. Courier Capital LLC bought a new stake in Invivyd during the fourth quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. acquired a new position in Invivyd during the fourth quarter valued at approximately $27,000. DRW Securities LLC acquired a new position in Invivyd during the fourth quarter valued at approximately $27,000. Finally, ProShare Advisors LLC bought a new position in shares of Invivyd in the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Insider Buying and Selling

In other Invivyd news, insider Jill Andersen sold 37,256 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total transaction of $26,824.32. Following the transaction, the insider directly owned 314,480 shares of the company’s stock, valued at $226,425.60. This represents a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 228,024 shares of company stock worth $176,540 over the last 90 days. Corporate insiders own 12.25% of the company’s stock.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
• Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
• Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.